196 related articles for article (PubMed ID: 35955915)
1. On the Aggregation of Apolipoprotein A-I.
Frankel R; Sparr E; Linse S
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955915
[TBL] [Abstract][Full Text] [Related]
2. Heparin and Methionine Oxidation Promote the Formation of Apolipoprotein A-I Amyloid Comprising α-Helical and β-Sheet Structures.
Townsend D; Hughes E; Hussain R; Siligardi G; Baldock S; Madine J; Middleton DA
Biochemistry; 2017 Mar; 56(11):1632-1644. PubMed ID: 27992182
[TBL] [Abstract][Full Text] [Related]
3. Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis.
Das M; Mei X; Jayaraman S; Atkinson D; Gursky O
FEBS J; 2014 Jun; 281(11):2525-42. PubMed ID: 24702826
[TBL] [Abstract][Full Text] [Related]
4. Identification of an amyloid fibril forming peptide comprising residues 46-59 of apolipoprotein A-I.
Wong YQ; Binger KJ; Howlett GJ; Griffin MD
FEBS Lett; 2012 Jun; 586(13):1754-8. PubMed ID: 22609356
[TBL] [Abstract][Full Text] [Related]
5. Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation.
Adachi E; Nakajima H; Mizuguchi C; Dhanasekaran P; Kawashima H; Nagao K; Akaji K; Lund-Katz S; Phillips MC; Saito H
J Biol Chem; 2013 Jan; 288(4):2848-56. PubMed ID: 23233678
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of aggregation and fibril formation of the amyloidogenic N-terminal fragment of apolipoprotein A-I.
Mizuguchi C; Nakagawa M; Namba N; Sakai M; Kurimitsu N; Suzuki A; Fujita K; Horiuchi S; Baba T; Ohgita T; Nishitsuji K; Saito H
J Biol Chem; 2019 Sep; 294(36):13515-13524. PubMed ID: 31341020
[TBL] [Abstract][Full Text] [Related]
7. Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?
Das M; Wilson CJ; Mei X; Wales TE; Engen JR; Gursky O
J Mol Biol; 2016 Jan; 428(2 Pt B):449-62. PubMed ID: 26562506
[TBL] [Abstract][Full Text] [Related]
8. The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils.
Adachi E; Kosaka A; Tsuji K; Mizuguchi C; Kawashima H; Shigenaga A; Nagao K; Akaji K; Otaka A; Saito H
FEBS Lett; 2014 Jan; 588(3):389-94. PubMed ID: 24316228
[TBL] [Abstract][Full Text] [Related]
9. Chameleon 'aggregation-prone' segments of apoA-I: A model of amyloid fibrils formed in apoA-I amyloidosis.
Louros NN; Tsiolaki PL; Griffin MD; Howlett GJ; Hamodrakas SJ; Iconomidou VA
Int J Biol Macromol; 2015 Aug; 79():711-8. PubMed ID: 26049118
[TBL] [Abstract][Full Text] [Related]
10. Effects of a lipid environment on the fibrillogenic pathway of the N-terminal polypeptide of human apolipoprotein A-I, responsible for in vivo amyloid fibril formation.
Monti DM; Guglielmi F; Monti M; Cozzolino F; Torrassa S; Relini A; Pucci P; Arciello A; Piccoli R
Eur Biophys J; 2010 Aug; 39(9):1289-99. PubMed ID: 20182709
[TBL] [Abstract][Full Text] [Related]
11. The polyphenol (-)-epigallocatechin-3-gallate prevents apoA-IIowa amyloidosis in vitro and protects human embryonic kidney 293 cells against amyloid cytotoxicity.
Nakajima H; Nishitsuji K; Kawashima H; Kuwabara K; Mikawa S; Uchimura K; Akaji K; Kashiwada Y; Kobayashi N; Saito H; Sakashita N
Amyloid; 2016; 23(1):17-25. PubMed ID: 26701221
[TBL] [Abstract][Full Text] [Related]
12. Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes.
Mizuguchi C; Ogata F; Mikawa S; Tsuji K; Baba T; Shigenaga A; Shimanouchi T; Okuhira K; Otaka A; Saito H
J Biol Chem; 2015 Aug; 290(34):20947-20959. PubMed ID: 26175149
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate remodels apolipoprotein A-I amyloid fibrils into soluble oligomers in the presence of heparin.
Townsend D; Hughes E; Akien G; Stewart KL; Radford SE; Rochester D; Middleton DA
J Biol Chem; 2018 Aug; 293(33):12877-12893. PubMed ID: 29853648
[TBL] [Abstract][Full Text] [Related]
14. Methionine oxidation induces amyloid fibril formation by full-length apolipoprotein A-I.
Wong YQ; Binger KJ; Howlett GJ; Griffin MD
Proc Natl Acad Sci U S A; 2010 Feb; 107(5):1977-82. PubMed ID: 20133843
[TBL] [Abstract][Full Text] [Related]
15. Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I.
Raimondi S; Guglielmi F; Giorgetti S; Di Gaetano S; Arciello A; Monti DM; Relini A; Nichino D; Doglia SM; Natalello A; Pucci P; Mangione P; Obici L; Merlini G; Stoppini M; Robustelli P; Tartaglia GG; Vendruscolo M; Dobson CM; Piccoli R; Bellotti V
J Mol Biol; 2011 Apr; 407(3):465-76. PubMed ID: 21296086
[TBL] [Abstract][Full Text] [Related]
16. Conformational and aggregation properties of the 1-93 fragment of apolipoprotein A-I.
Petrlova J; Bhattacherjee A; Boomsma W; Wallin S; Lagerstedt JO; Irbäck A
Protein Sci; 2014 Nov; 23(11):1559-71. PubMed ID: 25131953
[TBL] [Abstract][Full Text] [Related]
17. Myeloperoxidase-mediated Methionine Oxidation Promotes an Amyloidogenic Outcome for Apolipoprotein A-I.
Chan GK; Witkowski A; Gantz DL; Zhang TO; Zanni MT; Jayaraman S; Cavigiolio G
J Biol Chem; 2015 Apr; 290(17):10958-71. PubMed ID: 25759391
[TBL] [Abstract][Full Text] [Related]
18. ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity.
Liz MA; Gomes CM; Saraiva MJ; Sousa MM
J Lipid Res; 2007 Nov; 48(11):2385-95. PubMed ID: 17693625
[TBL] [Abstract][Full Text] [Related]
19. Heparin promotes fibril formation by the N-terminal fragment of amyloidogenic apolipoprotein A-I.
Mikawa S; Mizuguchi C; Nishitsuji K; Baba T; Shigenaga A; Shimanouchi T; Sakashita N; Otaka A; Akaji K; Saito H
FEBS Lett; 2016 Oct; 590(20):3492-3500. PubMed ID: 27654470
[TBL] [Abstract][Full Text] [Related]
20. Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I.
Andreola A; Bellotti V; Giorgetti S; Mangione P; Obici L; Stoppini M; Torres J; Monzani E; Merlini G; Sunde M
J Biol Chem; 2003 Jan; 278(4):2444-51. PubMed ID: 12421824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
